CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 42 enrolled
Drug / intervention
Lanabecestat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03019549
NCT03019549Phase 1Completed
CompareCT.gov

Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects

AstraZeneca·interventional·Posted Jan 12, 2017·Updated Nov 1, 2019

In Brief

A Phase 1 clinical trial evaluating Lanabecestat and Rosuvastatin for Healthy. Completed, enrolled 42 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be measured. Information about any side effects that may occur will also be collected. Participants will be on study for 21 days with a follow-up at least 7 days afterwards. Screening will be undertaken within 45 days prior to enrollment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 12, 2017
Enrollment StartJan 12, 2017
Primary CompletionMay 22, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.5 years ago

Interventions

Lanabecestatdrug

Administered orally

Rosuvastatindrug

Administered orally